Rugiet, the performance medicine company that’s helped more than 500,000 men take control of their health, today announced the expansion of its treatment areas to include longevity. Rugiet is bringing its physician-prescribed standards to an emerging wellness category dominated by unregulated sources with limited medical oversight. NAD+, Glutathione, Lipo-C, L-Carnitine, and Sermorelin are now available to Rugiet patients as prescribed compounds dispensed by a 503A compounding pharmacy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617982784/en/
Rugiet now offers physician-prescribed peptide and longevity therapies
Since its founding, Rugiet has helped men address issues ranging from sexual health and sleep to testosterone deficiency and weight management. Increasingly, the company found that patients were asking broader questions about energy, recovery, metabolic health, and how to maintain their vitality as they age. The expansion into longevity is a direct response to those needs, extending Rugiet’s physician-led approach into another area where demand is growing faster than access to trusted care.
Consumer demand for proactive solutions, including peptides, to optimize individual health has never been higher. Peptides are naturally occurring compounds that help regulate critical functions like recovery, metabolism, and healthy aging. In the absence of legitimate access, the gray market has emerged and grown rapidly. According to U.S. customs data, peptide imports from China nearly doubled to $328 million in the first three quarters of 2025, fueling a surge of unregulated operators selling research-only chemicals with no quality control or accountability.
Rugiet’s new longevity offerings are built to bring greater clinical oversight and accountability — every compound requires a prescription from a licensed U.S. physician, is dispensed by a 503A compounding pharmacy, is third-party tested for purity and potency, and is sourced to pharmaceutical-grade standards that Rugiet was founded upon. Patients will receive a personalized protocol built around their specific health profiles, a stark contrast to the one-size-fits-all solutions sold by the gray market. Rugiet is building the infrastructure that patients deserve and the standard the industry needs.
“We saw a tremendous opportunity to create a higher standard for a category that desperately needs one,” said Mike Apostal, CEO of Rugiet. “Our patients aren’t looking to just fix a problem and move on — they want to optimize their health at every stage. That’s what performance medicine is about. The gray market has stepped into a vacuum, and we’re built to fill it the right way: physician-led, pharmaceutical-grade, and accountable to the patients who trust us.”
Rugiet will enter longevity with three phases, beginning with NAD+, Glutathione, Lipo-C, L-Carnitine, and Sermorelin, available in injectable and nasal formats to Rugiet patients in a variety of personalized, physician-led treatment plans. This initial portfolio was selected with clinical credibility and patient fit in mind. With the addition of longevity therapies, Rugiet will continue to build the singular destination for men looking to take back their health — in areas including sexual health to sleep and testosterone replacement therapy.
- NAD+: Restores cellular energy. NAD+ levels naturally decline with age — replenishing them supports stamina, mental clarity, and metabolic function.
- Glutathione: Supports cellular defense against stress, immune function, and recovery.
- Lipo-C: Helps the body break down and mobilize stubborn fat — one of the most common symptoms Rugiet hears from male patients over 40.
- L-Carnitine: Transports fatty acids into cells to be burned as energy, supporting fat loss, endurance, and exercise recovery.
- Sermorelin: Ideal for men on Rugiet’s testosterone replacement therapy to maximize recovery, muscle performance, and sleep quality.
“Every treatment in Rugiet Health’s Longevity line undergoes the same rigorous evaluation process used across all our offerings, ensuring a comprehensive selection of high-quality solutions designed to meet each patient’s unique needs,” said Co-Founder and Chief Medical Officer of Rugiet, Vipul D. Khanpara, MD. “These five compounds earned their place because they each passed our rigorous qualification standards, a process that we refuse to abandon for any health solutions we create.”
Rugiet will also introduce an optional biomarker lab offering to give patients the clinical feedback loop that has been absent from this category. Labs will allow patients to track key health markers to ensure Rugiet’s protocols are working, adjusting treatments with Rugiet’s licensed physicians as more health insights become available. Phase three will introduce additional physician-prescribed peptides, pending the FDA’s advisory committee ruling on peptide reclassification in July.
For more information, visit rugiet.com/longevity.
ABOUT RUGIET
Since 2020, Rugiet has combined clinical authority with innovative, personalized treatments to help more than 500,000 men take control of their health. From sexual health and sleep, to weight management, testosterone and now longevity, we believe in not just fixing problems, but helping men optimize their health at every age. That’s performance medicine for men. Learn more at www.rugiet.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260617982784/en/
Media gallery
